Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expenses from Transactions with Related Party	$ 200,000		$ 200,000
Adimab Assignment Agreement [Member]
Related Party Transaction [Line Items]
Due to related parties	1,000,000.0		1,000,000.0		$ 600,000
Due from related parties	0		0		$ 0
Adimab Assignment Agreement [Member] | IPR&D Expense [Member]
Related Party Transaction [Line Items]
Revenue from related parties	0	$ 2,500,000	0	$ 3,500,000
Adimab Assignment Agreement [Member] | Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expenses from Transactions with Related Party	200,000	200	500,000	400,000
Adimab Collaboration Agreement [Member] | Research and Development Expense [Member]
Related Party Transaction [Line Items]
Revenue from related parties	1,300,000	0	2,600,000	0
Expenses from Transactions with Related Party	$ 600,000	$ 0	$ 1,000,000.0	$ 0
Series B Preferred Stock [Member] | Adimab [Member]
Related Party Transaction [Line Items]
Number of shares issued			44,076
Purchase price of shares			$ 2,500,000
Series C Preferred Stock [Member] | Adimab [Member]
Related Party Transaction [Line Items]
Number of shares issued			128,064
Purchase price of shares			$ 10,000,000.0